36 results about "Bezafibrate" patented technology

The invention relates to a controlled release preparation of bezafibrate. The controlled release preparation of bezafibrate contains a bezafibrate core and a semi-permeability film coating. The outer layer of the semi-permeability film coating is provided with a pore. The semi-permeability film coating is made of following components by mass proportion: 60 to 80 percent of polymer materials of the semi-permeability film coating and 20 to 40 percent of plasticizer. The polymer materials of the semi-permeability film coating are made by the mixture of one or more than one of cellulose acetate, ethyl cellulose, cellulose propionate, polycarbonate, polythene and PVA. The controlled release preparation of bezafibrate overcomes the 'peak valley' phenomenon of blood concentration existing in a common preparation and only needs to be taken once per day with the little adverse effect of a gastrointestinal tract, so a curative effect is ensured and patient compliance is also improved. The invention also relates to a preparation method of the controlled release preparation of bezafibrate.

The invention discloses an adulteration detection method to fibrates lipid-lowering chemicals of tea by the high-performance thin-layer chromatograph(HPTLC)-bioluminescent method and belongs to the technical field of food detection. The adulteration detection method includes, firstly, preparing standard product solution of bezafibrate and ciprofibrate and a tea sample; secondly, pre-washing thin-layer plates and performing HPTLC sample application; thirdly, performing HPTLC separation to move target objects mixed originally to different positions of the thin-layer plates according to difference of molecular structures so as to form physical isolation; finally, simultaneously detecting multiple targets of the samples conveniently through luminous strains coupled with the thin-layer plate byan impregnation method. The adulteration detection method refers to a method capable of detecting lipid-lowering chemicals of tea rapidly quantitatively by the HPTCL-bioluminescent method, and has the advantages of being economic, rapid, simple and convenient.

The present invention provides a therapeutic treatment for a neurodegenerative disease with a pan-PPAR agonist, such as bezafibrate. In particular, the present invention provides that pan-PPAR agonists enhance PPAR related responses in both the central nervous system and peripheral tissues in Huntington's Disease (HD) and tauopathy. Therapeutic compositions comprising one or more pan-PPAR agonist(s), and kit thereof, for treating a neurodegenerative disease or disorder are also provided.

The invention relates to an electrocatalytic particle electrode for efficiently degrading bezafibrate in wastewater and a preparation method thereof, belonging to the technical field of wastewater treatment. The preparation method comprises the following steps: uniformly mixing and stirring treated nonferrous metal slag, clay, a pore forming agent and an activator used as raw materials according to a certain weight ratio to prepare a mixed crude material, impregnating the mixed crude material in a carrier sol, drying, cooling to room temperature, extruding to obtain fresh pellets, drying, heating at specific temperature for activation and roasting for some time, taking out, and cooling to room temperature to obtain the finished product. The electrocatalytic particle electrode for efficiently degrading bezafibrate is porous, has large specific area, high adsorbability and favorable electrocatalytic property, and can degrade bezafibrate efficiently. The electrocatalytic particle electrode and preparation method thereof fully utilize the nonferrous metal slag, thereby changing the waste into valuable substances, reducing the environmental pollution and solving the problems of land occupation and the like.

The invention relates to a bezafibrate dual-release slow-release medicinal composition. The above dual-release capsule includes an immediate-release bezafibrate pellet and a slow-release bezafibrate pellet. The bezafibrate dual-release slow-release medicinal composition fills a gap in the market in China, and is convenient for clinical application.

The invention relates to a method for extracting high-efficiency bezafibrate degrading bacteria, which comprises the following steps: (1) inoculating activated sludge from a secondary sedimentation tank of an urban sewage treatment plant to an inorganic salt culture medium in an inoculation amount of 5 weight percent and domesticating for 2 months in a gradient pressure domestication way; and (2) standing a sample domesticated for 2 months for 30 minutes, taking 1mL of supernatant water sample for gradient dilution, inoculating 1mL of bacterial solution with each dilution concentration respectively to a solid culture medium for enrichment culture to ensure that a pure single strain is grown, and inoculating the pure single strain to a slant culture medium and storing at the temperature of 4 DEG C. In the method, the bezafibrate degrading bacterial strains are extracted from the activated sludge in the secondary sedimentation tank of the urban sewage treatment plant, so the bezafibrate degrading bacterial strains have the advantages of readily available source, simple and convenient separation and purification method, low cost and environmental protection; and the extracted bacterial strains have a bezafibrate degrading rate of over 85 percent and have good application prospect.

The present invention relates to the combined use of bezafibrate and of resveratrol or resveratrol derivatives for the treatment of diseases involving a mitochondrial energy dysfunction, and also to a pharmaceutical kit comprising both bezafibrate and resveratrol or resveratrol derivatives. The combination is more particularly used in the treatment of moderate defects of β-oxidation of long-chain fatty acids or of the respiratory chain of mitochondria.

The invention discloses a method for preparing a high-sensitivity bezafibrate molecular imprinting electrochemical sensor. According to the method, the high-sensitivity bezafibrate molecular imprinting electrochemical sensor is prepared from bezafibrate as template molecules, ceramide as a functional monomer, azodiisobutyronitrile as an initiator, a copper-zinc double-metal organic frame material as a doping agent and acetylshikonin as a cross-linking agent. The analysis method is simple and practical, and defects that a conventional analysis method is complex, expensive in equipment and low in sensitivity can be overcome.

The invention relates to the field of medicinal chemistry and discloses a synthesis method of bezafibrate for regulating blood fat. In the synthesis method, stabilized p-hydroxybenzene ethylamine hydrochloride and p-chlorobenzene formyl halide are used as initial raw materials to be substituted, hydrolyzed and condensed to obtain a target compound. The synthesis method has the advantages of low cost, mild reaction conditions, controllable processes and stable quality and is beneficial to industrialized production, the raw materials can be easily obtained and are relatively stabilized, the purity reaches 99.5% by the detection of the high performance liquid chromatography (HPLC), and the total yield is 48.1%.

The invention discloses a preparation method of bezafibrate. The preparation method is characterized in that N-p-hydroxybenzylethyl-4-chlorobenzamide, sodium hydroxide aqueous solution, acetone and a phase transfer catalyst are added to an organic solvent, chloroform is added dropwise to react, after the reaction is completed, water is added to the system to extract and stratify, the water layer is acidified, and the bezafibrate is obtained. In the preparation method, an organic solvent incompatible with water is added in the reaction, and the reaction is carried out in water condition, thus avoiding solvent distillation, rectification dehydration and the crushing of solid sodium hydroxide; and the preparation method shortens production cycle, reduces operation cost and improves operational safety, thus being favorable for industrialized production.

The invention discloses a purification method of bezafibrate in a preparation process. The purification method comprises the steps of evaporating and recycling solvent acetone after a synthesis reaction of the bezafibrate is finished, adding water to residues until the residues are clarified, adding hydrochloric acid to regulate the pH to be 11, introducing carbon dioxide into the water solution until no precipitate is generated, filtering, acidizing filter liquid until the pH of the filter liquid is 3-4, separating a product out, and filtering and washing to obtain a bezafibrate product. According to the purification method, unreacted raw materials are separated in an after-treatment stage of the synthesis reaction by virtue of acidity difference between the raw materials and the product, so that the content of the product is effectively increased, and the loss of the product caused by recrystallization is avoided.

The invention discloses a medicine compound against acute myeloid leukemia; each unit dose of the medicine compound contains 2mg of all-trans-retinoic acid, 1 to 2mg of megestrol acetate, 100 to 200mg of bezafibrate and a carrier acceptable of medical science, and the mass ratio of megestrol acetate to bezafibrate is 1:100. The medicine compound can significantly improve the survival rate of patients with acute myeloid leukemia, and can open up a new way for clinical treatment.

The invention relates to a composition capable of comprehensively improving blood lipid and insulin resistance state of a body at the same time, and belongs to the field of pharmacy. The composition comprises pharmaceutically acceptable doses of phenoxyaromatic acid drugs (including fenofibrate, bezafibrate, gemfibrozil, etc.) or pharmaceutically acceptable salts thereof, pharmaceutically acceptable doses of taurine and pharmaceutically acceptable carriers or excipients. The present invention also relates to that the composition is used to comprehensively control blood lipids of patients, including reducing total cholesterol (TC), low-density lipoprotein (LDL) and triglyceride (TG), and increasing high-density lipoprotein (HDL); simultaneously the present invention The composition involved can be used to treat metabolic syndrome, synergistically improve the insulin resistance state of the body, and improve the insulin sensitivity index, and its effect is obviously better than that of a single medicine. The present invention also relates to the application of the composition in the preparation of medicines for the treatment of living bodies with dyslipidemia or metabolic syndrome.